Company intelligence / Profile preview

Jenscare Scientific

Ningbo, Zhejiang, Chinaen.jenscare.com ↗

Ownership: Private
Employees: ~211
Development stage: Other

Overview

Jenscare’s LuX-Valve Plus transcatheter tricuspid valve replacement system has demonstrated safety and efficacy in the TRAVEL II trial for severe tricuspid regurgitation at high surgical risk. The device achieved short delivery times, low composite event rates, significant reduction of tricuspid regurgitation severity and improved quality of life metrics at one year. Other pipeline products are advancing through confirmatory or feasibility clinical trials.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Implantable Medical Devices

Partnerships

Not explicitly listed in public sources as of June 2025.

Beyond the preview

Go deeper on Jenscare Scientific.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jenscare Scientific.

Explore the full profile